Decreased incidence of febrile neutropenia in Michigan following masking and social distancing orders for the COVID-19 pandemic: A population based cohort study

Table 2 Frequency of clinical relevant group diagnosis among patients with neutropenic and febrile neutropenia in Year 0 and Year 1

	Neutropenia			Febrile neutropenia
	Year 01	Year 12	P value	Year 01	Year 12	P value
Diagnoses	n = 3276	n = 2441		n = 740	n = 505
Common infections	1482 (45)	974 (40)	< 0.0001	403 (55)	255 (51)	0.17
Any malignancy	1237 (38)	833 (34)	0.01	276 (37)	182 (36)	0.65
Solid malignancies	722 (22)	511 (21)	0.32	120 (16)	101 (20)	0.09
Hematologic malignancies	564 (17)	357 (15)	0.01	165 (22)	85 (17)	0.02
Benign neoplasms	147 (5)	111 (5)	0.91	43 (6)	17 (3)	0.05
Non-malignant blood dyscrasias	1580 (48)	1213 (50)	0.27	315 (43)	227 (45)	0.41
Endocrine, nutritional, and metabolic disorders	1485 (45)	1119 (46)	0.70	268 (36)	200 (40)	0.23
Skin, musculoskeletal, psychiatric, and nervous system disorders	1224 (37)	870 (36)	0.18	211 (29)	134 (27)	0.44
Disorders of the cardiopulmonary system	1639 (50)	1125 (46)	0.003	324 (44)	210 (42)	0.44
Disorders of the gastrointestinal and genitourinary systems	1332 (41)	952 (39)	0.21	226 (31)	159 (32)	0.72
Coronavirus disease 2019	6 (0)	207 (9)	< 0.0001	0 (0)	45 (9)	-

¹Includes the 13 mo prior to Michigan’s state-wide public health executive orders (PHEO) and coronavirus disease 2019 (COVID-19) mitigation efforts; March 1, 2019 to March 31, 2020.

²Includes the 13 mo following Michigan’s state-wide PHEO and COVID-19 mitigation efforts; April 1, 2020 to April 31, 2021.

Data reported at n (%) unless otherwise specified.